Availability and Access to Medications for Puberty Induction and Maintenance in Adolescents with Hypogonadism in the Arab Region

A. Deeb 1,2, H. AlSaffar 3, R. T. Hamza 4, M. Abass 1, and A. M. Habeb 5

1Sheikh Shakhbout Medical City, Abu Dhabi, UAE
2Faculty of Health Science, Khalifa University, Abu Dhabi, UAE
3Faculty of Medicine, Sultan Qabus University, Muscat, Oman
4Faculty of Medicine, Ain Shams University, Cairo, Egypt
5Pediatric Department, Prince Mohammed Bin Abdulaziz Hospital, Ministry of National Guard, Madinah, Saudi Arabia

Correspondence should be addressed to A. Deeb; adeeb@ssmc.ae

Received 16 April 2022; Revised 21 May 2022; Accepted 7 June 2022; Published 20 July 2022

Academic Editor: Sanja Stankovic

Copyright © 2022 A. Deeb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Inducing puberty in hypogonadal patients enables achieving normal final adult height and healthy bone mass accrual and improves fertility potential. Reliable availability and access to medicines remain a challenge around the world, particularly in low-income countries. Aim. We aimed to describe the availability/access to medications used for inducing and maintaining puberty in centers within the Arab region. Method. A cross-sectional survey was conducted using a link to an online questionnaire, which was emailed to paediatric endocrinologists in the Arab region. The questionnaire consisted of three questions related to the availability of various forms of sex hormones. Results. 99 physicians from 16 countries participated in the study. The commonest available form of estrogen was conjugated estrogen (29% of centers), followed by ethinylestradiol (26%). Depot estradiol was available in 11 centers, while topical estrogen preparations of gel and patches were available in 6 and 10 centers, respectively. Medroxy progesterone was available in 26% of the centers, followed by norethisterone (24%). The combined forms of oral and transdermal patches of estrogen/progesterone were available in 35% and 9% of centers, respectively. Intramuscular testosterone (Sustanon) was the most commonly available preparation of testosterone, followed by the depot injection (Nebido), oral testosterone, and testosterone gel and cream. Conclusions. We report the first available data on medications used for puberty induction and maintenance in paediatric hypogonadism in the Arab region. Recommended preparations for this purpose are not widely available. Creating an essential list of medications used in paediatric endocrinology disorders might improve availability, access, and consequently practice.

1. Introduction

Paediatric endocrinology is a specialty with many rare conditions and relatively high-cost medicines. Hypogonadism is a condition of sex hormone deficiency that results either from primary gonadal dysfunction or secondary hypogonadotropic causes.

In hypogonadal girls, estradiol deficiency causes endothelial dysfunction, reduced insulin production, an abnormal lipid profile, increased central adiposity, and the formation of early atheroma [1]. Inducing puberty in hypogonadal girls and boys enables patients to achieve normal final adult height and healthy bone mass accrual. It also alleviates psychological distress and improves fertility potential [2].

Estrogens, progestins, and androgens are agents used to induce and maintain puberty. These agents have different pharmacokinetics and dynamics compared to endogenous steroids [3]. The World Health Organization (WHO) first created an Essential Medicines List (EML) for children in 2007, 30 years after the first EML for adults. Hormones are listed in the complimentary (rather than core) list of WHO
essential medicines considering that they require specialized diagnostic, monitoring facilities, specialist medical care, and specialist training [4]. To date, there are no clinical practice guidelines providing a master list of medicines used for paediatric endocrinology.

Reliable and sustainable availability and access to medicines remain a challenge around the world, with the poorest and most vulnerable populations at the highest risk of failing to secure access. Up to a third of the population lacks reliable sources for needed medicines. This proportion reaches higher than 50% in some countries in Asia and Africa [5]. Some business model initiatives have been tried to improve access to essential medicines in limited resource countries and have shown a positive impact on availability [6]. However, these models were restricted to certain medications in limited areas.

Access to medicines that are used in high-income countries remains low in many low-middle-income countries and prevents appropriate lifelong management of paediatric endocrine conditions [7]. Medications listed in the complimentary essential list of WHO (like most hormones) are usually linked to a higher price, which remains a major barrier for obtaining them.

Clinical practice guidelines in the management of hypogonadism within paediatric endocrinology are variable. The choice of preparations used for inducing and maintaining puberty in males and females differs between Europe, the United States (US), and the Arab region [8–10]. The lack of universal guidelines in the management of hypogonadism might contribute to the limited availability of recommended preparations.

To the best of our knowledge, there is no data related to the availability and access to medications used to induce and maintain puberty in hypogonadism within the Arab region.

1.1. Aim. We aim to study the availability/access to medications used for inducing and maintaining puberty in female and male hypogonadism in centers within the Arab region.

2. Materials and Methods

2.1. Study Design. This cross-sectional survey was conducted between July and October 2019 using commercial software (Survey Monkey, USA). An invitation with a link to the online questionnaire was emailed to paediatric endocrinologists registered in the Arab Society of Paediatric Endocrinology and Diabetes (ASPED) database. This was followed by three reminders over the study period. The invitation outlined the purpose of the study, the voluntary nature of the contribution, the unconditional right to decline participation, and opting out from the database. Strict confidentiality of participants’ details was ensured and data were collected anonymously. The study was approved by the ASPED council. Considering that the study was survey-based utilizing a questionnaire for health care professionals without direct patient contact, research ethics approval was not deemed necessary. Health care professionals were asked to tick on a field of consent at the beginning of the survey, confirming their willingness to participate in the study.

2.2. The Questionnaire. A comprehensive literature search on the study area was undertaken by the co-authors. A questionnaire was drafted in relation to the availability of different forms of medications used for the induction and maintenance of puberty in girls and boys. A hard copy of the draft was distributed during the 5th ASPED-ESPE (European Society of Paediatric Endocrinology) endocrine school in 2018 [11] and was validated by the school participants (12 consultants and 41 trainees). The final version of the questionnaire was approved by all co-authors and uploaded to the survey website.

The survey questionnaire was in English, which is the official language for educational communication between physicians in the region, and included three questions. Different preparations of estrogen, progesterone, and testosterone were listed in the three questions, respectively. Participants were asked to select all the available preparations in their center of practice from the list and add “others” as free text if they were not listed in the question (Table 1).

3. Results

Two hundred and seventy-three physicians opened the invitation e-mail. Of those, 99 completed the questionnaire, giving a response rate of 36.3%. All 99 physicians answered all the three questionnaire questions and indicated that they manage five to over 20 patients with hypogonadism annually. The physicians were practicing in 99 different centers in 16 Arab countries: Morocco, Algeria, Tunisia, Libya, Egypt, Sudan, Jordan, Iraq, Lebanon, Palestine, Oman, Kuwait, Qatar, the Kingdom of Saudi Arabia (KSA), and the United Arab Emirates (UAE).

Forty-nine centers were from the Gulf countries, while 50 were from North Africa and the Levant countries. The highest response rate was from Oman (19%), followed by Saudi Arabia (16%) and Iraq (13%). Eight out of the 99 centers were private, while the rest were governmental institutions (Figure 1).

3.1. Estrogen Preparations Availability. The commonest available form of estrogen was conjugated estrogen, which was available in 26 (29%) government and 3 (38%) private centers in 10 countries. This was followed by ethinylestradiol, which was available in 24 (26%) and two government and private centers, respectively, from 11 countries. Estriified estrogen and 17β estradiol were available in 15 and 11 centers in 8 and 6 countries, respectively. Depot estradiol was available in 11 centers in five countries. Topical preparations of estradiol, transdermal patches, and estradiol gel were available in 10 and 6 centers, in 8 and 4 centers, respectively (Table 2).

3.2. Progesterone and Combined Hormones Preparations Availability. Medroxy progesterone was available in 24 (26%) centers (2 private) in seven countries. This is followed by norethisterone, which was available in 22 (24%) centers in eight countries, while Utrogestan was available in eight centers in 3 countries. The combined forms of estrogen/
Table 1: List of questions asked in the survey.

| Question 1 | Question 2 | Question 3 |
|------------|------------|------------|
| Testosterone | Estrogen | Progesterone and combined preparations |
| Intramuscular testosterone (sustanon) | Conjugated estrogen | Norethisterone |
| Oral testosterone undecanoate | Ethinyl estradiol | Utrogestan |
| Depot testosterone injection (nebido/Reandron) | Estrified estrogen | Medroxyprogesterone |
| Testosterone cream 5% | Depot estradiol injection | Combined estrogen/progestin pills |
| Transdermal testosterone gel | 17β estradiol | Combined estrogen/progestin patches |
| Testosterone patch | Transdermal estradiol patch | |
| Testosterone cream 5% | Estradiol gel | |

Table 2: Available estradiol, progesterone, and combined pills preparations within countries and centers. (G) indicates government centers.

| Medicine | No. of centers (G) | No. of countries | Which countries |
|----------|--------------------|------------------|-----------------|
| Conjugated estrogen | 29 (26) | 10 | Algeria, Libya, Sudan, UAE, KSA, Iraq, Kuwait, Oman, Jordan, Qatar |
| Ethinylestradiol | 26 (24) | 11 | Algeria, Egypt, Sudan, Palestine, Jordan, Iraq, Qatar, Oman, UAE, KSA, Kuwait |
| Estrified estrogen | 15 (13) | 8 | Tunisia, Algeria, Iraq, Jordan, KSA, Oman, UAE, Kuwait |
| 17β estradiol | 11 (8) | 6 | Algeria, Sudan, Tunisia, Iraq, UAE, Palestine |
| Depot estadiol | 11 (11) | 5 | Iraq, Qatar, Egypt, Jordan, Kuwait |
| Transdermal estradiol patches | 10 (9) | 8 | KSA, Oman, Iraq, Palestine, Egypt, Algeria, Lebanon, KSA |
| Estradiol gel | 6 (4) | 4 | Algeria, Iraq, Oman, KSA |
| Combined pills (OCP) | 32 (30) | 9 | Algeria, Egypt, Iraq, KSA, Oman, Kuwait, Qatar, UAE, Sudan |
| Oral: Norethisterone | 22 (21) | 8 | Egypt, Sudan, Libya, Iraq, Jordan, KSA, UAE, Oman, |
| Utrogestan | 8 (6) | 3 | Algeria, Tunisia, UAE |
| Medroxy progesterone | 24 (22) | 7 | Egypt, Sudan, Iraq, KSA, Oman, UAE, Kuwait |
| Combined patches | 8 (2) | 5 | Iraq, Palestine, Algeria, Oman, KSA |
progesterone enquired about were combined contraceptive pills (OCP) and combined hormone patches. The former was available in 32 (35%) centers in nine countries, while the latter was available in eight (9%) centers in five countries (Table 2).

3.3. Testosterone Preparations Availability. Intramuscular testosterone (Sustanon) was the most available form of testosterone as it was available in all 16 countries. Sixty-one (67%) government centers and 8 (100%) private centers have access to this preparation of testosterone. Depot injection of testosterone (Nebido or Reandron) was available in 11 (12%) government centers and one (12.5%) private center in 6 countries (KSA, Egypt, Palestine, Yemen, Iraq, and Oman). Oral testosterone preparation (testosterone undecanoate) was available in seven centers (one private) in five countries (KSA, Palestine, Oman, Iraq, and UAE). Testosterone cream is available in five government centers in Iraq and Egypt, while transdermal gel of 1% and 2% is available in four government centers in Iraq, Kuwait, and Palestine. One government center in Iraq had a transdermal patch. Three participants from three government centers in Iraq and Egypt indicated the availability of dihydrotestosterone (DHT) gel (Table 3).

3.4. Overall Preparations Availability. The most commonly available preparation was intramuscular testosterone (Sustanon), which was noted to be available in all countries and the majority of the centers. Oral estrogen preparations, conjugated estrogen and ethinyl estradiol, were available in 29 and 26 centers in 10 and 11 countries, respectively. Oral medroxy progesterone and norethisterone were available in eight countries (24 and 22 centers, respectively). Testosterone undecanoate was available in seven centers in five countries. In regards to the patches preparations, transdermal estrogen patch and combined estrogen/progesterone patches were available in eight countries, while testosterone patches were available in only one. Estradiol gel was available in 4 countries while testosterone gel of 1% and 2% was available in 3 countries (Figure 2).

A comparison of individual preparation availability between Gulf and non-Gulf countries did not show any significant difference for any of the preparations.

4. Discussion

In October 2003, the WHO regional office in Cairo conducted a presurvey workshop on medicine availability and price measurement using the WHO/Health Action International (HAI) methodology [12]. It was followed by a medicine price survey conducted in nine Arab countries (Jordan, Kuwait, Lebanon, Morocco, Pakistan, Sudan, Syria, Tunisia, and Yemen) [13]. The workshop and the survey showed that the availability of essential medications in public health facilities is generally suboptimal and needs improvement. The report showed that the availability of medicines is lower in the public sector than in the private sector. Medicines available in the public sector are usually generics, while those in the private sector are more likely to be of originator brands [12, 13]. In this study, we were not able to study the difference in availability between government and private centers as the number of the latter was low.

Various explanations have been suggested for the variations in the selection of medication preparations to treat specific diseases. This is applicable to the choice of hormone preparation used to treat hypogonadism. Availability and access are among the factors influencing choice. In a previous study by our group, there was a difference in the selection of estrogen preparations by paediatric endocrinologists in Arab countries compared to the USA and Europe [10]. European and American guidelines recommend starting puberty induction with ethinylestradiol and conjugated estradiol, respectively [8, 9]. Both preparations were available only in a quarter of the participating centers in this study. This might result in the use of ethinylestradiol in girls, with progestins introduced only after a period of unopposed estrogen. Starting progestins without prior estrogenization results in uterine growth compromise, particularly with preparations that have more androgenic effects such as norethisterone [14]. Oral ethinyl estradiol was the most common form of estrogen prescribed by Arab physicians (29.7%), followed by oral conjugated estrogen (16.5%). Based on our current study, the varied selection cannot be attributed purely to availability, as ethinylestradiol and conjugated estrogen were equally available in about a third of participating centers (Figure 2). The choice of one preparation or the other can be due to different prescription routines or training backgrounds in addition to availability. However, accessibility can be a deciding factor in the choice of preparation. An example of the availability influencing choice is the selection of oral 17 β-estradiol, which was chosen by only 10% of practitioners in the Arab countries compared to 32% in Europe [8] and none in the USA [9]. The availability of oral 17 β estradiol in participating centers is restricted to 11%, which could be the reason for the low percentage of selection (Figure 2). The use of estradiol patches is not high in our study or others. Patches were selected by 11.5% of Arab, 10% of European, and 7.8% of USA respondents [8–10] despite being more physiological. This could be explained by the lack of availability of the preparation in our region. Less than 10% of participating centers have this form available (Figure 2). There is increasing evidence that ethinylestradiol is inferior to transdermal estradiol in terms of blood pressure and bone density, which makes transdermal estradiol the preparation of choice [9]. However, it was not a popular selection among Arab practitioners [10]. This study confirmed that lack of availability of this preparation might be the main reason for not using it, as patches were available only in one center among the 8 private centers that participated and only 9 out of the government centers. One of the problems in deciding which agents to use for pubertal induction is the lack of good quality randomized controlled trials. However, there are some useful data in a number of observational studies.
highlighting specific dose responses and bio-equivalency of estrogen products. The results of these studies have the practical implications of some replacement dosage use, particularly in patients on multiple medications, including growth hormone [15].

80% of participants in our previous study [10] preferred IM testosterone esters. This choice was comparable to the USA survey [9], where it was selected by 87.8% of respondents. Androgen depot esters have been tried for over 50 years. They are known to be safe and have physiological pharmacokinetics. Intramuscular testosterone (Sustanon) was scored as the highest available medication in our study (Figure 2), with 69 (70%) centers from all countries stocking it. Long-acting testosterone depot preparation is less commonly available, with only 12% of centers from six countries indicating its availability (Table 1). In our previous study, there was a trend of using oral testosterone undecanoate in the Gulf states compared to other Arab countries [10]. While we speculated that the higher availability of this form in the Gulf might explain this trend, we could not confirm this speculation as we found no statistically significant difference in its availability between Gulf and non-Gulf countries ($P = 0.2301$).

Availability and selection of agents for treatment are interrelated issues. It is difficult to assume which results in the other. Ideally, a decision on choice is made by specialists on evidence-based grounds, which then ensures availability. This approach could be achieved by creating national essential medicine lists, which could be country (or possibly region) specific. Lists need to address the disease burden of the nation/region and include drugs used in various national health programmes. Creating these lists will not only reflect the relative disease burden but also highlight commonly used therapeutic interventions that need to be made affordable, accessible, and available. These lists can be potentially powerful instruments to ensure that medicines are available, accessible, and of good quality, resulting in strengthening health equity [16]. Inclusion of more endocrine medications in WHO EMLs may promote the adoption of more medicines by individual countries within their national EML. To improve paediatric endocrinology

| Medicine               | No. of centers (G) | No. of countries | Which countries                                    |
|------------------------|--------------------|-----------------|---------------------------------------------------|
| IM T (sustanon)        | 69 (61)            | 16              | All countries                                     |
| T depot (nebido/Reandron) | 12 (11)           | 6               | KSA, Egypt, Palestine, Yemen, Iraq, Oman          |
| Testosterone undecanoate | 7 (6)             | 5               | KSA, Palestine, Oman, Iraq, UAE                   |
| Testosterone cream 5%  | 5 (5)              | 2               | Iran, Egypt                                       |
| Transdermal gel: T 1%, 2% | 4 (4)            | 3               | Iraq, Kuwait, Palestine                           |
| T patch                | 1 (1)              | 1               | Iraq                                              |

Figure 2: Overall list of medications in order of availability in countries and centers within countries.
medication availability, Rowlands et al. recommended amending the cut-off age for children using physical maturity rather than the actual age. Also, to encourage formatting of the EMLs in a disease-focused manner rather than as individual medicines [17]. On this issue, WHO ELM lists testosterone preparation as testosterone enanthate 200 mg/ml preparation, which is less frequently used compared to depot preparations. Listing the concentration of the preparation is another issue. For example, testosterone is listed as a 25 mg/ml testosterone propionate in the Indian national ELM when it is not the mostly used preparation nor the recommended dose/concentration [18]. The same applies for estrogens where ethinylestradiol 0.01 and 0.05 mg are listed for use at primary, secondary, and tertiary levels while lower-dose estrogen pills suitable for younger girls with hypogonadism are not listed [18].

One of the main challenges in inducing puberty in girls is the lack of licensed products, with treatment frequently recommended by using off-label formulations intended for adults. In addition, while transdermal products are more physiological, they may be perceived as more difficult to use or less acceptable than oral products. Furthermore, there is very little information on specific dose-response or bioequivalency of oral or transdermal 17β estradiol. These factors might influence prescription practice, and consequently, the availability of these preparations.

Overall, we noticed that there were fewer issues with testosterone preparation compared to estrogens. This might be attributed to the wider variety of estrogen preparations compared to testosterone, which requires more validated studies to recommend one form over the other.

As for the progestin preparation, the recommended form is utrogestan 200 mg once daily [19]. This is a natural micronized progesterone which provides good cycle control and is the least androgenic. Only eight centers out of 99 had this preparation available. Medroxyprogesterone was available in about a quarter of the centers from seven countries. Norethisterone was equally available but was not the preferred preparation to use considering its potent androgenic effect and its link to a higher incidence of dysmenorrhea [20].

Our study has many limitations. One issue was the low response rate, which makes it difficult to assume representation of a whole country based on the centers which responded from that country.

In conclusion, we report the first data on the availability of medications used for puberty induction and maintenance in boys and girls with hypogonadism in the Arab region. Recommended preparations for this purpose are not widely available within the Arab region. Creating an essential list of medications used in paediatric endocrinology disorders might improve availability, access and consequently practice.

Data Availability

Data supporting the results are available from the corresponding author. The preprint submission is cited in the reference section.

Disclosure

The article was presented in preprint format in the research square, https://www.biorxiv.org/content/10.1101/2020.10.27.356808v1 [21].

Conflicts of Interest

None of the authors has any conflicts of interest to declare.

Authors' Contributions

All the authors designed the study collectively. A. Deeb coordinated the study tasks, supervised the overall work, and wrote the initial draft. H. Al Saffar managed the survey distribution and data analysis. R. T. Hamza and A. M. Habeb revised the manuscript.

Acknowledgments

Sheikh Shakhbout Medical City Education Department covered the publication fees of this article.

References

[1] M. L. Davenport, “Approach to the patient with turner syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1487–1495, 2010.
[2] M. R. Palmert and L. Dunkel, “Delayed puberty,” New England Journal of Medicine, vol. 366, no. 5, pp. 443–453, 2012.
[3] M. Zacharin, “Disorders of puberty: pharmacotherapeutic strategies for management,” Handbook of Experimental Pharmacology, vol. 261, pp. 507–538, 2020.
[4] WHO, Model List of Essential Medicines, 21st List, WHO, Geneva, Switzerland, 2019.
[5] “Who pays for health systems?, in world health report 2000,” Available at: https://www.who.int/whr/ 2000.
[6] H. Nusser, T. Salimuthal, and V. Canon, “Business model initiatives to improve access to essential medicines in limited resources countries. a pharmaceutical company’s approach,” The American Journal of Tropical Medicine and Hygiene, vol. 101, no. 5, p. 221, 2019.
[7] I. C. M. Emmerick, V. L. Luiza, L. A. B. Camacho, C. Vialle-Valentin, and D. Ross-Degnan, “Barriers in household access to medicines for chronic conditions in three Latin American countries,” International Journal for Equity in Health, vol. 14, no. 1, p. 115, 2015.
[8] W. Kiess, G. Conway, M. Ritzen et al., “Induction of puberty in the hypogonadal girl–practices and attitudes of pediatric endocrinologists in Europe,” Hormone Research in Pediatrics, vol. 57, no. 1-2, pp. 66–71, 2002.
[9] S. Drobac, K. Rubin, A. D. Rogol, and R. L. Rosenfield, “A workshop on pubertal hormone replacement options in the USA,” Journal of Pediatric Endocrinology & Metabolism: Journal of Pediatric Endocrinology & Metabolism, vol. 19, no. 1, pp. 55–64, 2006 Jan.
[10] R. T. Hamza, A. Deeb, H. Al Saffar, S. H. Alani, and A. J. Habeb, “Timing and regimen of puberty induction in children with hypogonadism: a survey on the practice in Arab countries,” Pediatr Endocrinol Metab, vol. 18, 2020.
[11] A. Habe, R. T. Hamza, and A. Deeb, “The 5th combined school of the Arab society for pediatric endocrinology and diabetes (ASPED) and European society for pediatric
endocrinology (ESPE), 2018: a model for inter-societies collaboration,” *Libyan Journal of Medicine*, vol. 14, no. 1, Article ID 1652059, 2019.

[12] A. Hussein, *Gezairy: Report on the WHO Regional Training Workshop on Medicine Prices*, Cairo, Egypt, 2010.

[13] WHO, *Medicine prices, availability, affordability and price components. A Synthesis Report of Medicine Price Survey Undertaken in Selected Countries of the WHO Eastern Mediterranean Region*, WHO, Geneva, Switzerland, 2005.

[14] A. L. Isotton, M. C. O. Wender, A. Casagrande, G. Rollin, and M. A. Czepielewski, “Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study,” *European Journal of Endocrinology*, vol. 166, no. 2, pp. 207–213, 2012.

[15] V. K. Bakalov, T. Shawker, I. Ceniceros, and C. A. Bondy, “Uterine development in turner syndrome,” *The Journal of Pediatrics*, vol. 151, no. 5, pp. 528–531.e1, 2007.

[16] N. J. Gray, J. P. Chanoine, M. Y. Farmer et al., “NCDs and the WHO essential medicines lists: children need universal health coverage too,” *The Lancet Child & Adolescent Health*, vol. 3, no. 11, pp. 756-757, 2019.

[17] A. Rowlands, A. Acosta-Gualandri, J. Guevara-Aguirre, and J. P. Chanoine, “WHO and national lists of essential medicines in Mexico, central and south America, and the Caribbean: are they adequate to promote paediatric endocrinology and diabetes care?” *BMJ Global Health*, vol. 1, no. 3, Article ID e000114, 2016.

[18] S. Kalra, S. Bajaj, and A. Mithal, “Endocrinology and the essential list,” *Indian Journal of Endocrinology and Metabolism*, vol. 16, no. 8, p. S133, 2012.

[19] D. Matthews, L. Bath, W. Högler et al., *Guidance Statement: Hormone Supplementation for Pubertal Induction in Girls*, 2016.

[20] A. Deeb, H. AlSaffar, R. T. Hamza, and A. Habeeb, “Availability of medications used for puberty induction and maintenance in adolescents with hypogonadism in the Arab region,” 2020.

[21] https://www.biorxiv.org/content/10.1101/2020.10.27.356808v1.